Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab with Trastuzumab and Pertuzumab in HER2+ Metastatic Breast Cancer
NCT03135171Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Recommended Phase II Dose at 10 weeks. Started Jul 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03135171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135171.